Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the inc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Oncol
Päätekijät: Swain, S. M., Schneeweiss, A., Gianni, L., Gao, J. J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M. S., Yoo, B., Cortes, J., Baselga, J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834072/
https://ncbi.nlm.nih.gov/pubmed/28057664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw695
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia